Insider Selling: United Therapeutics (NASDAQ:UTHR) Director Sells $1,655,790.00 in Stock

United Therapeutics Corporation (NASDAQ:UTHR) Director Christopher Patusky sold 2,910 shares of the firm’s stock in a transaction dated Friday, April 24th. The stock was sold at an average price of $569.00, for a total transaction of $1,655,790.00. Following the completion of the transaction, the director owned 1,490 shares in the company, valued at approximately $847,810. The trade was a 66.14% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website.

Christopher Patusky also recently made the following trade(s):

• On Friday, April 17th, Christopher Patusky sold 1,000 shares of United Therapeutics stock. The stock was sold at an average price of $578.88, for a total transaction of $578,880.00.

United Therapeutics Stock Performance

United Therapeutics stock opened at $567.16 on Monday. The firm’s 50-day moving average is $536.51 and its 200-day moving average is $494.61. United Therapeutics Corporation has a 1 year low of $272.12 and a 1 year high of $607.89. The company has a market cap of $24.86 billion, a P/E ratio of 20.33, a PEG ratio of 1.61 and a beta of 0.75.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings results on Wednesday, February 25th. The biotechnology company reported $7.70 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $6.78 by $0.92. United Therapeutics had a net margin of 41.94% and a return on equity of 19.30%. The company had revenue of $790.20 million for the quarter, compared to the consensus estimate of $814.80 million. During the same period last year, the firm posted $6.19 EPS. The company’s revenue for the quarter was up 7.4% on a year-over-year basis. As a group, sell-side analysts predict that United Therapeutics Corporation will post 27.97 earnings per share for the current year.

Institutional Trading of United Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Strs Ohio lifted its stake in shares of United Therapeutics by 68.2% in the 1st quarter. Strs Ohio now owns 27,614 shares of the biotechnology company’s stock worth $16,375,000 after acquiring an additional 11,198 shares during the period. Root Financial Partners LLC lifted its stake in shares of United Therapeutics by 134.8% in the 1st quarter. Root Financial Partners LLC now owns 324 shares of the biotechnology company’s stock worth $192,000 after acquiring an additional 186 shares during the period. IFM Investors Pty Ltd acquired a new stake in shares of United Therapeutics in the 1st quarter worth approximately $5,264,000. Lansforsakringar Fondforvaltning AB publ raised its holdings in United Therapeutics by 0.3% during the first quarter. Lansforsakringar Fondforvaltning AB publ now owns 13,396 shares of the biotechnology company’s stock worth $7,944,000 after purchasing an additional 39 shares in the last quarter. Finally, Apollon Wealth Management LLC bought a new stake in United Therapeutics during the first quarter worth approximately $7,880,000. 94.08% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

UTHR has been the topic of several recent research reports. Raymond James Financial initiated coverage on shares of United Therapeutics in a research report on Friday, April 10th. They issued an “outperform” rating and a $700.00 price objective on the stock. Jefferies Financial Group reiterated a “buy” rating on shares of United Therapeutics in a research report on Monday, March 2nd. HC Wainwright lifted their price objective on shares of United Therapeutics from $600.00 to $660.00 and gave the company a “buy” rating in a research report on Tuesday, March 31st. Bank of America lifted their price objective on shares of United Therapeutics from $569.00 to $626.00 and gave the company a “neutral” rating in a research report on Tuesday, March 31st. Finally, Weiss Ratings reiterated a “buy (b)” rating on shares of United Therapeutics in a research report on Monday, December 29th. Ten analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to data from MarketBeat.com, United Therapeutics has an average rating of “Moderate Buy” and a consensus target price of $601.50.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.